Alex Oh
Corporate Officer/Principal bei DYNAVAX TECHNOLOGIES CORPORATION
Aktive Positionen von Alex Oh
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
DYNAVAX TECHNOLOGIES CORPORATION | Corporate Officer/Principal | 01.01.2022 | - |
Karriereverlauf von Alex Oh
Ehemalige bekannte Positionen von Alex Oh
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Stoel Rives LLP
Stoel Rives LLP Miscellaneous Commercial ServicesCommercial Services Stoel Rives LLP provides full suite of transactional and litigation solutions for U.S. and international clients. Its practice areas include corporate, energy, environmental, intellectual property, labor and employment, land use and construction, litigation, natural resources, real estate, renewable energy and technology law. The firm?s clients include financial institutions, public and private utilities, energy and renewable energy companies, developers, manufacturers, retailers, hospitals, universities, agribusinesses, software companies, food and beverage companies, charitable foundations, telecommunications and forestry companies, among others. The company was founded in 1907 and is headquartered in Portland, OR. | Corporate Officer/Principal | - | - |
JUNO THERAPEUTICS INC | General Counsel | - | - |
Technology & Intellectual Property Group | Corporate Officer/Principal | - | - |
Visus Therapeutics, Inc.
Visus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation. | General Counsel | - | - |
Ausbildung von Alex Oh
University of Washington | Undergraduate Degree |
University of Wisconsin | Graduate Degree |
University of Wisconsin Law School | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 8 |
Kanada | 2 |
Operativ
Corporate Officer/Principal | 3 |
General Counsel | 2 |
Undergraduate Degree | 2 |
Sektoral
Health Technology | 4 |
Consumer Services | 4 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
DYNAVAX TECHNOLOGIES CORPORATION | Health Technology |
Private Unternehmen | 4 |
---|---|
Stoel Rives LLP
Stoel Rives LLP Miscellaneous Commercial ServicesCommercial Services Stoel Rives LLP provides full suite of transactional and litigation solutions for U.S. and international clients. Its practice areas include corporate, energy, environmental, intellectual property, labor and employment, land use and construction, litigation, natural resources, real estate, renewable energy and technology law. The firm?s clients include financial institutions, public and private utilities, energy and renewable energy companies, developers, manufacturers, retailers, hospitals, universities, agribusinesses, software companies, food and beverage companies, charitable foundations, telecommunications and forestry companies, among others. The company was founded in 1907 and is headquartered in Portland, OR. | Commercial Services |
Technology & Intellectual Property Group | |
Juno Therapeutics, Inc.
Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA. | Health Technology |
Visus Therapeutics, Inc.
Visus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation. | Health Technology |